“Our clinical assets are both highly promising a
Post# of 72445
(Total Views: 277)
Posted On: 09/20/2018 11:51:53 AM
“Our clinical assets are both highly promising and well-diversified,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis; to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available, to commence work on new product formulations—1) an oral pill for Kevetrin in Ovarian Cancer; 2) an oral pill for Brilacidin in IBD; and a topical application for Brilacidin in Atopic Dermatitis and Acne.”
Does this mean they already have the $$ to analyze Prurisol data?
Does this mean they already have the $$ to analyze Prurisol data?
(1)
(0)